CJC-1295 vs Sermorelin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
CJC-1295 is a synthetic GHRH analog with a Drug Affinity Complex (DAC) that binds circulating albumin, extending half-life from 7 minutes to approximately 6-8 days. Enables once-weekly dosing with sustained GH elevation. Phase I/II clinical research status. WADA prohibited under ...
Calculate CJC-1295 dose →Sermorelin is a synthetic analog of the first 29 amino acids of endogenous GHRH, retaining full biological activity at the GHRH receptor. It was FDA approved (Geref) for GH deficiency in children from 1997 until its voluntary market withdrawal in 2008 for commercial reasons - not...
Calculate Sermorelin dose →| Parameter | CJC-1295 | Sermorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| Research | Extensively Studied | Extensively Studied |
| Half-Life | ~6–8 days (with DAC) | ~10–20 min |
| Typical Dose | 1–2 mg | 200–500 µg |
| Frequency | Once weekly or twice weekly | Once daily (bedtime) |
| Route | Subcutaneous | Subcutaneous |
| FDA Status | Not Approved | Compounding Only |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.